Cargando…

A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients

BACKGROUND AND AIM OF THE WORK: BRCA1/2 are tumour-suppressor genes involved in DNA homologous recombination and ovarian cancer development. The study evaluated the risk of tumor cancer in women presenting the BRCA mutations. METHODS: Risk-reducing surgery (RRS) was performed in 100 patients carryin...

Descripción completa

Detalles Bibliográficos
Autores principales: Loizzi, Vera, Cicinelli, Ettore, Del Vecchio, Vittoria, Arezzo, Francesca, Deromemaj, Xheni, Kardhashi, Anila, Paradiso, Angelo, Legge, Francesco, Natalicchio, Maria Iole, Resta, Leonardo, Resta, Nicoletta, Loconte, Daria Carmela, Cormio, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534247/
https://www.ncbi.nlm.nih.gov/pubmed/36043985
http://dx.doi.org/10.23750/abm.v93i4.11695
Descripción
Sumario:BACKGROUND AND AIM OF THE WORK: BRCA1/2 are tumour-suppressor genes involved in DNA homologous recombination and ovarian cancer development. The study evaluated the risk of tumor cancer in women presenting the BRCA mutations. METHODS: Risk-reducing surgery (RRS) was performed in 100 patients carrying BRCA1 (aged between 30-73 years, median age was 51 years) and BRCA 2 mutation (aged between 36-70 years, median age was 53 years). Fifty-eight patients had previous history of breast cancer. RESULTS: Between the 100 patients, 82 women underwent risk-reducing salpingo-oophorectomy (RRSO) through a laparoscopic minimally invasive approach, 7 (7%) underwent laparoscopic RRSO and contextual hysterectomy, 1 woman (1%) underwent RRSO through a laparotomic approach and 10 women (10%) laparotomic RRSO and hysterectomy. During 5 (5%) laparoscopic RRSO, prophylactic bilateral mastectomy was also performed. Early and late complication occurred in 3 patients (3%). Two patients (2%) were found to have occult Serous Tubal Intraepithelial Carcinoma (STIC) and three patients (3%) occult cancer. CONCLUSIONS: RRSO is safe and feasible in BRCA mutation carriers. The procedure is effective for genetic prevention of ovarian cancer. (www.actabiomedica.it)